Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

15603 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-10-31

Study Completion Date

2005-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE:

* Atherothrombosis is a progressive and generalized vascular disease resulting in events leading to myocardial infarction (heart attack), stroke, and vascular death.
* In patients at risk for this disease, it is characterized by an unpredictable, sudden disruption of atherosclerotic plaques, which may lead to total occlusion of artery due to formation of a clot. The use of aspirin (blood thinner agent) for reducing those major ischemic events is either indicated, or recommended by international guidelines. However, aspirin fails to prevent a high percentage of such life-threatening events. Therefore, more effective blood thinning therapy may provide additional clinical benefit to such patients.
* The results of the CURE trial in patients with unstable angina demonstrate the additional benefit of long-term treatment (up to one year) with clopidogrel, (a blood thinner agent), when administered in combination with standard therapy including aspirin. The purpose of CHARISMA is to investigate whether a similar clinical benefit of clopidogrel may apply to a broad population of high-risk patients receiving low-dose aspirin therapy. Such population includes patients with previous cardiovascular, neurovascular or peripheral arterial manifestations of atherothrombosis and patients with combinations of recognized risk factors for atherosclerosis.

OBJECTIVES:

* To assess the efficacy of clopidogrel 75 mg once-daily by comparison with a placebo, in preventing cardiovascular morbidity/mortality. The study will compare the efficacy of the two regimens in preventing the occurrence of major cardiovascular complications (stroke, heart attack, cardiovascular death) in high-risk patients who are otherwise receiving low-dose aspirin therapy (75-162 mg daily).
* To evaluate the safety of clopidogrel in this population, and more specifically the incidence of fatal or severe bleeding (as per GUSTO definition), in order to estimate the global benefit of clopidogrel in this patient population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clopidogrel in High-risk Patients With Acute Non-disabling Cerebrovascular Events

NCT00979589

Stroke Transient Ischemic Attack

COMPLETED PHASE3

SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3

NCT04418479

Coronary Artery Disease

COMPLETED PHASE4

A Study to Assess the Effect of SB 659032 on Platelet Function

NCT01750827

Atherosclerosis

COMPLETED PHASE1

Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction

NCT00714961

Acute Coronary Syndromes

COMPLETED PHASE3

Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment

NCT00386191

Cerebral Infarction

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

TREATMENTS:

* Clopidogrel (Plavix® and/or Iscover®) is an agent inhibiting platelet aggregation involved in clot formation. Each tablet contains 75mg of clopidogrel. A matching placebo of clopidogrel is an inactive substance that looks similar to the active clopidogrel tablet.

TREATMENT PLAN:

* There will be two treatment groups; one will receive clopidogrel 75 mg (1 tablet qd), the second matching placebo of clopidogrel (1 tablet qd). These study drugs will be administered on top of low-dose aspirin (75-162 mg qd) systematically prescribed to such patients. In addition, patients enrolled in CHARISMA will be managed as appropriate for their risk factors for atherosclerosis: eg. high blood pressure, high cholesterol, diabetes…etc.

PRIMARY ENDPOINT:

* Combined endpoint of cardiovascular mortality, stroke, acute myocardial infarction.

STUDY EXECUTION:

* Some 7,600 patients per group will be recruited within two years. Patients will be observed over a maximum of 3.5 years.

STUDY TERRITORY:

* Approximately 900 sites throughout North/South America, Europe, Asia, Australia, and South Africa.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arteriosclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

clopidogrel (SR25990)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Combination of atherothrombotic risk factors (2 major or 3 minor or 1 major + 2 minor risk factors among those listed below)

Major atherothrombotic risk factors

* Type I or II diabetes (under drug therapy)
* Diabetic nephropathy
* Ankle brachial index (ABI) \< 0.9
* Asymptomatic carotid stenosis \>= 70%
* At least one carotid plaque as evidenced by intima-media thickness (IMT)

Minor atherothrombotic risk factors

* Systolic blood pressure (SBP) \>= 150 mmHg, despite appropriate therapy for at least 3 months
* Primary hypercholesterolemia
* Current smoking \> 15 cigarettes per day
* Male \>= 65 years
* Female \>= 70 years

and/or

* Documented cerebrovascular disease (TIA or IS within 5 years) and/or
* Documented coronary artery disease (stable angina with documented multivessel coronary disease, previous documented MI, multivessel PCI or CABG within 1 year, multivessel CABG older than 1 year associated with current angina) and/or
* Documented symptomatic PAD

EXCLUSION:

* Absolute indication for the use of clopidogrel, high-dose aspirin (\>162 mg), NSAIDs, or oral anti-thrombotic drugs
* Absolute contraindication to the use of clopidogrel or aspirin
* Clinical conditions likely to interfere with follow-up leading to inability to complete the trial

Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

sanofi-aventis

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ICD CSD

Role: STUDY_DIRECTOR

Sanofi

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Cleveland Clinic Foundation

Cleveland, Ohio, United States

Site Status

Sanofi-aventis Administrative Office

Buenos Aires, , Argentina

Site Status

Sanofi-aventis Administrative Office

Macquarie Park, , Australia

Site Status

Sanofi-aventis Administrative Office

Vienna, , Austria

Site Status

Sanofi-aventis Administrative Office

Diegem, , Belgium

Site Status

Sanofi-aventis Administrative Office

São Paulo, , Brazil

Site Status

Sanofi-aventis Administrative Office

Laval, , Canada

Site Status

Sanofi-aventis Administrative Office

Santiago, , Chile

Site Status

Sanofi-aventis Administrative Office

Prague, , Czechia

Site Status

Sanofi-aventis Administrative Office

Hørsholm, , Denmark

Site Status

Sanofi-aventis Administrative Office

Helsinki, , Finland

Site Status

Sanofi-aventis Administrative Office

Paris, , France

Site Status

Sanofi-aventis Administrative Office

Berlin, , Germany

Site Status

Sanofi-aventis Administrative Office

Athens, , Greece

Site Status

Sanofi-aventis Administrative Office

Causeway Bay, , Hong Kong

Site Status

Sanofi-aventis Administrative Office

Budapest, , Hungary

Site Status

Sanofi-aventis Administrative Office

Milan, , Italy

Site Status

Sanofi-aventis Administrative Office

Kuala Lumpur, , Malaysia

Site Status

Sanofi-aventis Administrative Office

México, , Mexico

Site Status

Sanofi-aventis Administrative Office

Gouda, , Netherlands

Site Status

Sanofi-aventis Administrative Office

Lysaker, , Norway

Site Status

Sanofi-aventis Administrative Office

Warsaw, , Poland

Site Status

Sanofi-aventis Administrative Office

Porto Salvo, , Portugal

Site Status

Sanofi-aventis Administrative Office

Moscow, , Russia

Site Status

Sanofi-aventis Administrative Office

Singapore, , Singapore

Site Status

Sanofi-aventis Administrative Office

Midrand, , South Africa

Site Status

Sanofi-aventis Administrative Office

Barcelona, , Spain

Site Status

Sanofi-aventis Administrative Office

Bromma, , Sweden

Site Status

Sanofi-aventis Administrative Office

Geneva, , Switzerland

Site Status

Sanofi-aventis Administrative Office

Taipei, , Taiwan

Site Status

Sanofi-aventis Administrative Office

Istanbul, , Turkey (Türkiye)

Site Status

Sanofi-aventis Administrative Office

Guildford Surrey, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Austria Belgium Brazil Canada Chile Czechia Denmark Finland France Germany Greece Hong Kong Hungary Italy Malaysia Mexico Netherlands Norway Poland Portugal Russia Singapore South Africa Spain Sweden Switzerland Taiwan Turkey (Türkiye) United Kingdom